Literature DB >> 15504827

Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

Quinton L Fivelman1, Ipemida S Adagu, David C Warhurst.   

Abstract

A modified fixed-ratio isobologram method for studying the in vitro interactions between antiplasmodial drugs is described. This method was used to examine the interactions between atovaquone, proguanil, and dihydroartemisinin. The interaction between atovaquone and proguanil was synergistic against atovaquone-sensitive strains K1 and T996; however, there was a loss of synergy against atovaquone-resistant strain NGATV01 isolated after Malarone (the combination of atovaquone and proguanil) treatment failure. While the interaction between atovaquone and dihydroartemisinin was indifferent against isolate NGATV01, the interaction displayed indifference tending toward antagonism against the atovaquone-sensitive strains tested. The relevance of in vitro interactions to in vivo treatment is discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504827      PMCID： PMC525430          DOI： 10.1128/AAC.48.11.4097-4102.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum.

Authors:  S Gupta; M M Thapar; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Synergism between arteether and mefloquine or quinine in a multidrug-resistant strain of Plasmodium falciparum in vitro.

Authors:  R Ekong; D C Warhurst
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Nov-Dec       Impact factor: 2.184

3.  Preventing antimalarial drug resistance through combinations.

Authors:  N J White
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

4.  Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.

Authors:  Anna Färnert; Johan Lindberg; Pedro Gil; Göte Swedberg; Yngve Berqvist; Mita M Thapar; Niklas Lindegårdh; Sándor Berezcky; A Björkman
Journal:  BMJ       Date:  2003-03-22

5.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Authors:  B Høgh; P D Clarke; D Camus; H D Nothdurft; D Overbosch; M Günther; I Joubert; K C Kain; D Shaw; N S Roskell; J D Chulay
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

Review 6.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Authors:  S Looareesuwan; J D Chulay; C J Canfield; D B Hutchinson
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

7.  Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

Authors:  I K Srivastava; H Rottenberg; A B Vaidya
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

8.  Reversal of chloroquine resistance in Plasmodium falciparum by verapamil.

Authors:  S K Martin; A M Oduola; W K Milhous
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

Review 9.  Combination therapy for malaria: the way forward?

Authors:  François Nosten; Philippe Brasseur
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

Authors:  I K Srivastava; A B Vaidya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191
View more
  129 in total

1.  In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.

Authors:  Rodrigo Hinojosa Valdez; Lilian Tatiani Düsman Tonin; Tânia Ueda-Nakamura; Sueli Oliveira Silva; Benedito Prado Dias Filho; Edilson Nobuyoshi Kaneshima; Sueli Fumie Yamada-Ogatta; Lucy Megumi Yamauchi; Maria Helena Sarragiotto; Celso Vataru Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

2.  Synergistic anti-malarial action of cryptolepine and artemisinins.

Authors:  Arnold D Forkuo; Charles Ansah; Kwesi M Boadu; Johnson N Boampong; Elvis O Ameyaw; Ben A Gyan; Andrea T Arku; Michael F Ofori
Journal:  Malar J       Date:  2016-02-16       Impact factor: 2.979

3.  Tetrahydrophthalazinone Inhibitor of Phosphodiesterase with In Vitro Activity against Intracellular Trypanosomatids.

Authors:  Julianna Siciliano de Araújo; Raiza Brandão Peres; Patrícia Bernardino da Silva; Marcos Meuser Batista; Geert Jan Sterk; Louis Maes; Guy Caljon; Rob Leurs; Harry P de Koning; Titilola D Kalejaiye; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  A small-molecule inhibitor of the DNA recombinase Rad51 from Plasmodium falciparum synergizes with the antimalarial drugs artemisinin and chloroquine.

Authors:  Pratap Vydyam; Dibyendu Dutta; Niranjan Sutram; Sunanda Bhattacharyya; Mrinal Kanti Bhattacharyya
Journal:  J Biol Chem       Date:  2019-04-01       Impact factor: 5.157

6.  Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

7.  Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.

Authors:  Julianna Siciliano de Araújo; Cristiane França da Silva; Denise da Gama Jaén Batista; Aline Nefertiti; Ludmila Ferreira de Almeida Fiuza; Cristina Rosa Fonseca-Berzal; Patrícia Bernardino da Silva; Marcos Meuser Batista; Maarten Sijm; Titilola D Kalejaiye; Harry P de Koning; Louis Maes; Geert Jan Sterk; Rob Leurs; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

8.  Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.

Authors:  Valter V Andrade-Neto; Karina M Rebello; Thais M Pereira; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

9.  Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.

Authors:  Cristiana T Trinconi; Juliana Q Reimão; Jenicer K U Yokoyama-Yasunaka; Danilo C Miguel; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.

Authors:  Yejin Jang; Jin Soo Shin; Yi-Seul Yoon; Yun Young Go; Hye Won Lee; Oh Seung Kwon; Sehee Park; Man-Seong Park; Meehyein Kim
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.